Nasus Pharma

growth-positive

Nasus Pharma Ltd., a clinical-stage pharmaceutical company, has announced a strategic collaboration with Aptar France S.A.S. and AptarGroup, Inc., leading global manufacturers of drug delivery systems. This partnership aims to support the clinical development and commercialization of Nasus Pharmas intranasal powder epinephrine product candidate, NS002. The collaboration provides Nasus Pharma with access to Aptars proven Unit Dose System technology, manufacturing capabilities, and regulatory expertise, which will accelerate NS002s path to market and reduce development risks. The partnership is a significant milestone for Nasus Pharma, enhancing its clinical and commercial roadmap for NS002.

growth-positive

Nasus Pharma Ltd., a clinical-stage pharmaceutical company, is set to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025. The company specializes in developing innovative intranasal products for emergency medical conditions, with a focus on a needle-free alternative to Epinephrine autoinjectors for anaphylaxis. Their proprietary powder-based intranasal technology aims for rapid and reliable drug delivery. The presentation will be led by CEO Dan Teleman, and management will be available for one-on-one meetings with interested investors. This event highlights Nasus Pharmas ongoing efforts in advancing their clinical-stage products and engaging with the investment community.

growth-positive

Nasus Pharma Ltd., a clinical-stage pharmaceutical company, recently celebrated a significant milestone by ringing the Closing Bell at the New York Stock Exchange (NYSE) on August 25, 2025. This event marked the companys recent listing on the NYSE and highlighted its progress in developing innovative intranasal products aimed at treating emergency medical conditions such as severe allergic reactions and anaphylaxis. Nasus Pharmas proprietary intranasal powder technology offers a needle-free, fast-acting alternative to traditional treatments, providing peace of mind for families dealing with anaphylaxis. The companys mission is to transform emergency medicine through innovation and patient care.

growth-positive

Nasus Pharma, Ltd., a clinical-stage pharmaceutical company, announced the closing of its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, raising $10 million in gross proceeds. The shares began trading on the NYSE American LLC exchange under the ticker symbol NSRX. The company plans to use the proceeds to further develop its intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies. Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC acted as joint bookrunners for the offering. Nasus Pharma is focused on developing innovative intranasal products for emergency medical conditions, leveraging its proprietary powder-based intranasal technology.

growth-positive

Nasus Pharma, Ltd., a clinical-stage pharmaceutical company based in Tel Aviv, announced the pricing of its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, aiming to raise $10 million. The company focuses on developing intranasal products for emergency medical conditions, specifically its Epinephrine program. The proceeds from the IPO will be used for manufacturing scale-up and additional Phase 2 studies, as well as general corporate purposes. The shares are expected to begin trading on the NYSE American LLC under the ticker symbol NSRX on August 13, 2025. Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC are the joint bookrunners for the offering.

growth-positive

Nasus Pharma, an Israeli company specializing in powder-based intranasal treatments, has successfully completed its IPO, raising $10 million at a valuation of $75 million. This IPO is notable as it comes during a period of declining share prices in the pharmaceutical sector and a scarcity of IPOs from Israeli companies. Nasus Pharmas flagship product, NS002, is an intranasal powder epinephrine candidate designed as a needle-free alternative for anaphylaxis treatment. The companys proprietary technology aims to provide rapid and reliable drug delivery through the nasal cavity. The IPO was managed by Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC.

growth-positive

Nasus Pharma Ltd., a clinical-stage biopharmaceutical company, is set to present results from two clinical studies at the 2025 AAAAI Annual Scientific Meeting. The studies focus on the pharmacokinetics and pharmacodynamics of their intranasal epinephrine product, FMXIN002, in both healthy volunteers and atopic patients. FMXIN002 is a needle-free, powder-based intranasal spray designed to treat anaphylaxis, offering advantages over existing epinephrine self-injectors. The product uses APTARs Nasal Unidose Powder device for easy and precise drug delivery. Nasus Pharma aims to address acute medical conditions like anaphylactic shock and opioid overdose with its intranasal powder technology. The presentation is scheduled for March 1, 2025, in San Diego, California.

growth-positive

Nasus Pharma, a leading biopharma company, reassures the public about the safety and clinical efficacy of its nasal spray, Taffix. The company emphasizes that Taffix is safe and legally marketed in Europe under CE certification. It is indicated for use as a protective barrier against allergens and viruses, including SARS-CoV-2. Nasus Pharma disagrees with the classification of Taffix as a Medical Device Class III in Spain, as it is classified as a Class I product in other countries. Laboratory tests show that Taffix destroys up to 99% of the coronavirus, and a user survey found that it reduces the risk of infection by 78%. Taffix is sold in over 20 countries and is not a replacement for masks but an additional layer of protection.

growth-negative

Spanish drug regulators have banned the sale of Taffix nasal spray, which was touted as a potential coronavirus treatment. The spray, manufactured by Nasus Pharma, was credited with preventing Covid infections at a religious festival in Israel. However, the medical regulators in Spain and the UK have banned its sale due to a lack of clinical evidence of its effectiveness. Experts warn that unproven Covid remedies may give people false confidence and lead to riskier behavior. The spray claims to block 97% of all airborne viruses and has a CE mark for safety. Despite lab-based studies showing its efficacy, there is limited real-world research. Nasus Pharma has not announced plans for rigorous scientific trials. The spray has no known side effects but may cause a tingling or burning sensation in the nose.

growth-positive

Israeli biopharmaceutical company Nasus Pharma is developing a nasal spray device called Taffix to prevent the spread of COVID-19. The spray creates a protective layer in the nasal passages, preventing viruses from reaching the receptors cells in the nose. Nasus Pharma conducted a user survey during the Jewish High Holidays, testing the spray on a group of worshippers in the city of Bnei Brak. The results showed a significant reduction in infection rates among those who used the spray compared to those who did not. Taffix has been approved in Europe, the Dominican Republic, and Israel. Nasus Pharma plans to continue testing the spray in other populations and circumstances.

growth-positive

Nasus Pharma has developed a powder-based medical device called TaffiX that coats the nasal passages with a clear hydroxypropyl methylcellulose (HPMC) jelly to prevent viruses, including COVID-19, from entering the body via the nose. The product is sold in the EU with claims of preventing COVID-19 and other viruses. However, it is not yet approved by the Israeli Health Ministry for COVID-19 prevention. Nasus Pharma CEO Dr. Dalia Megiddo expressed concerns about the long-term effects of a COVID-19 vaccine and the logistical challenges of shipping and handling vaccines that require cold storage. Megiddo has a history of investing in and working on orphan drugs to cure rare diseases.

growth-positive

Nasus Pharmas nasal powder inhaler, TaffiX, has been found to effectively block more than 99% of SARS-CoV-2 viruses. The inhaler creates an acidic microenvironment in the nose, preventing viruses from entering and infecting nasal cells. The gel layer produced by TaffiX powder blocks the virus and reduces the amount of infectious live virus. Nasus Pharma intends to pursue Emergency Use Authorization from the US FDA to increase global availability of the product. The studys results demonstrate the versatility of the technology and its potential as a first line of protection against respiratory viruses, including SARS-CoV-2.

growth-positive

Nasus Pharma announced data from a preclinical collaboration with the University of Virginia School of Medicine, demonstrating that their nasal powder inhaler, TaffiX, effectively blocks more than 99% of SARS-CoV-2 viruses. The study showed that TaffiX created a gel layer that blocked the virus and reduced the amount of infectious live virus by more than 99%. Nasus Pharma intends to pursue Emergency Use Authorization from the U.S. FDA based on these positive results. TaffiX is currently approved for marketing in Europe and Israel as a protective barrier against allergens and viruses within the nasal cavity. The company believes that TaffiX could be an important tool in preventing SARS-CoV-2 infections.